Image

ctDNA Based MRD Testing for NAC Monitoring in TNBC

Recruiting
18 years of age
Female
Phase N/A

Powered by AI

Overview

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.

Description

NeXT Personal CTA (Clinical Trial Assay) is a patient-specific, tumor-informed device which allows for detection of MRD from cfDNA. By using next generation sequencing technology, whole genome sequencing (WGS) is conducted from DNA derived from patient tumor and normal samples. A tumor informed personalized panel is then constructed that uses only a selection of DNA targets from the WGS by applying bioinformatic filters. The targeted personalized panel is then sequenced using NGS and DNA derived from cfDNA from plasma samples. The data from the cfDNA NGS are then further analyzed using bioinformatics filters to report the MRD status.

Eligibility

Inclusion Criteria:

  1. Have histologically documented TNBC (defined as ER expression ≤10% by IHC, PR expression≤10% by IHC and HER2 0 or 1+ by IHC or FISH ratio <2 or HER2 gene copy number of <6).
  2. Early-stage breast cancer (stage I-III) and scheduled to undergo NAC treatment with curative intent.
  3. Be informed of the investigational nature of the study and all pertinent aspects of the trial.
  4. Have the ability to understand and the willingness to sign a written informed consent document in accordance with institutional and federal guidelines.
  5. Be ≥ 18years of age.
  6. Patient who are scheduled to start NAC.
  7. Be willing to provide blood samples before and during treatment.
  8. Have available biopsy tissue.

Exclusion Criteria:

  1. Receiving concurrent anti-neoplastic therapy for another malignancy.
  2. Stage IV disease.
  3. Current or history of another primary cancer within 5 years of study entry, with the exception of basal or squamous cell skin cancer, or non-invasive malignancy.
  4. History of allogeneic bone marrow or organ transplant.
  5. Blood transfusion within two weeks before collection of blood for central ctDNA testing.
  6. Started systemic therapy for their breast cancer.
  7. Pregnancy

Study details

TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease

NCT06230185

Personalis Inc.

15 February 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.